Select therapeutic use:
Indications for COMBIVIR:
Adults and Children:
<30kg: not recommended. ≥30kg: 1 tab twice daily. Hepatic or renal impairment (CrCl <50mL/min): not recommended; use individual components.
Risk of hematologic toxicity/bone marrow suppression; monitor CBCs esp. in advanced HIV-1 disease; interrupt dose if anemia or neutropenia occurs. Myopathy with prolonged zidovudine use. Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Not for treating hepatitis B; monitor patients co-infected with HBV for at least several months after stopping treatment (discontinuing may exacerbate HBV infection). History of pancreatitis. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
See full labeling. Concomitant stavudine, doxorubicin, ribavirin, emtricitabine, other forms of lamivudine or zidovudine: not recommended. Increased hematologic toxicity with ganciclovir, interferon alpha, other bone marrow suppressants or cytotoxic drugs. TMP/SMX, nelfinavir may potentiate lamivudine. Atovaquone, clarithromycin, fluconazole, methadone, nelfinavir, probenecid, rifampin, ritonavir, valproic acid may affect zidovudine levels; monitor. Monitor for treatment-associated toxicities (eg, hepatic decompensation) with interferon-alpha with or without ribavirin.
Nucleoside analogues (reverse transcriptase inhibitors).
Headache, nausea, malaise, fatigue, nasal symptoms, diarrhea, cough; neutropenia, anemia, lactic acidosis, severe hepatomegaly with steatosis, fat redistribution, myopathy, myositis, immune reconstitution syndrome, post-treatment exacerbation of hepatitis B, pancreatitis (discontinue if occurs).
Register pregnant patients exposed to lamivudine by calling (800) 258-4263.